리도카인 염산염 시장 : 제형, 용도, 제품 유형, 최종사용자별 - 세계 예측(2024-2032년)

Global Lidocaine Hydrochloride Market will witness 5.5% CAGR between 2024 and 2032, driven by the increasing number of product launches from leading companies. Lidocaine hydrochloride, a local anesthetic commonly used for pain management in medical and dental procedures, is seeing expanded applications and innovations. New formulations and delivery systems are being introduced to enhance efficacy, patient comfort, and ease of use. Leading pharmaceutical companies are developing novel products such as extended-release formulations, transdermal patches, and combination therapies that offer improved pain relief and longer-lasting effects. For instance, in March 2023, Sintetica S.A., a global pharmaceutical company with manufacturing facilities in Switzerland, announced the launch of Lidocaine Hydrochloride Injection, USP in concentrations of 1%, 2%, and 4%, through its subsidiary, Sintetica US.

These innovations are responding to rising patient and healthcare provider demands for more effective and convenient pain management solutions. Additionally, as regulations and standards evolve, companies are investing in research and development. The continuous introduction of advanced lidocaine hydrochloride products is expected to drive market growth, meeting the increasing need for effective pain management across various therapeutic areas.

The overall Lidocaine Hydrochloride Industry value is classified based on the dosage form, application, product type, end-user, and region.

Based on dosage form, the lidocaine hydrochloride market revenue from the creams segment will register a commendable CAGR from 2024 to 2032. Lidocaine hydrochloride creams are widely used for their effective numbing properties, providing relief from localized pain, itching, and discomfort caused by conditions such as sunburn, insect bites, and minor skin irritations. The convenience and non-invasiveness of topical creams make them highly appealing to consumers seeking quick and effective relief. As awareness of pain management options increases and preferences shift towards non-prescription, over-the-counter solutions, the market for lidocaine hydrochloride creams is expected to grow, driven by consumer demand for accessible and efficient pain relief products.

In terms of application, the cardiology segment will witness an appreciable growth from 2024 to 2032. Lidocaine hydrochloride is used intravenously to stabilize heart rhythms during acute cardiac events, such as ventricular arrhythmias, and to prevent complications during procedures. Its efficacy in quickly stabilizing abnormal heart rhythms and its well-established safety profile make it a preferred choice in emergency and routine cardiac care. As advancements in cardiology continue and the focus on effective arrhythmia management grows, the demand for lidocaine hydrochloride is expected to rise, reflecting its essential role in contemporary cardiac treatment protocols.

Europe lidocaine hydrochloride market will exhibit a notable CAGR from 2024 to 2032. In Europe, lidocaine hydrochloride is integral to various medical procedures, including local anesthesia for dental work, minor surgeries, and pain relief for chronic conditions. The growing emphasis on patient comfort, minimally invasive procedures, and effective pain management is driving demand. Additionally, the European focus on advancing healthcare standards and the approval of new formulations are contributing to market growth. As healthcare providers seek reliable and efficient anesthetic solutions, the demand for lidocaine hydrochloride in Europe continues to rise, reflecting its vital role in medical care.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidences of chronic pain and cardiovascular diseases
    • 3.2.1.2 Increasing number of surgery procedures
    • 3.2.1.3 Advancements in drug delivery systems
    • 3.2.1.4 Increasing preference for anesthetics over opioids
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects associated with lidocaine
    • 3.2.2.2 Stringent regulatory complexities
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porters analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Creams
• 5.3 Patches
• 5.4 Injectables
• 5.5 Other dosage forms

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Cardiology
• 6.3 Dental procedures
• 6.4 Epilepsy
• 6.5 Dermatological procedures
• 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Generics
• 7.3 Branded

Chapter 8 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Clinics
• 8.4 Ambulatory surgical centers (ASCs)
• 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AdvaCare Pharma
• 10.2 Amneal Pharmaceuticals LLC
• 10.3 AstraZeneca Plc.
• 10.4 B. Braun Melsungen AG
• 10.5 Endo Pharmaceuticals Inc.
• 10.6 Fresenius SE & Co. KGaA
• 10.7 F. Hoffmann-La Roche Ltd.
• 10.8 Gensco Pharma
• 10.9 Glenmark Pharmaceuticals
• 10.10 Guanlang Group
• 10.11 Hisamitsu Pharmaceutical Co., Inc.
• 10.12 Mylan N.V.
• 10.13 PAI Pharma.
• 10.14 Pfizer Inc.
• 10.15 Scilex Holding Company
• 10.16 Septodont Healthcare India Pvt. Ltd.
• 10.17 Taro Pharmaceutical Industries Ltd.